APP (gene)

APP (gene). The amyloid beta precursor protein gene, located on chromosome 21, encodes a transmembrane protein that is ubiquitously expressed and plays roles in synaptic formation, neurite outgrowth, and cell adhesion. It is most widely studied due to its central role in the pathogenesis of Alzheimer's disease, as its proteolytic processing generates amyloid-beta peptides, the primary component of senile plaques. Research on this gene spans molecular biology, neuroscience, and clinical neurology, making it a critical focus for understanding neurodegeneration.

Gene and protein structure

The APP gene is located on the long arm of chromosome 21 at band 21.3 and consists of 18 exons. Through alternative splicing, it gives rise to several protein isoforms, with the 695-amino-acid variant being predominant in neurons. The encoded protein is a single-pass type I transmembrane protein with a large extracellular N-terminus, a short transmembrane domain, and a small cytoplasmic C-terminus. Key domains include the E1 domain and E2 domain, which are involved in protein-protein interactions, and the amyloid-beta region itself, which is partly embedded within the transmembrane segment. The structure is conserved across many species, from Drosophila melanogaster to mammals.

Function and biological role

The normal physiological functions of the APP protein are diverse and not fully elucidated. It is involved in synaptic plasticity and is thought to act as a cell surface receptor, potentially interacting with extracellular matrix components and other proteins like Fez1. Its role in iron export from neurons has been proposed, linking it to metal homeostasis. During development, APP promotes neurite outgrowth, cell adhesion, and neuronal migration. Proteolytic cleavage by secretase enzymes, including alpha-secretase and beta-secretase, releases various soluble fragments, such as sAPPalpha, which may have neurotrophic and neuroprotective effects, indicating a complex dual role in cell signaling and neuronal survival.

Clinical significance and Alzheimer's disease

The primary clinical significance of APP lies in its causative link to Alzheimer's disease. Pathogenic missense mutations within the APP gene, such as the Swedish mutation and the London mutation, are responsible for some forms of early-onset familial Alzheimer's disease. These mutations alter proteolytic processing, favoring the amyloidogenic pathway mediated by beta-secretase and gamma-secretase, leading to increased production of aggregation-prone amyloid-beta peptides, particularly the 42-amino-acid form (Aβ42). The accumulation of Aβ42 into oligomers and fibrils drives the formation of extracellular plaques, neuroinflammation, synaptic dysfunction, and ultimately neuronal death, hallmarks observed in the brains of patients with Alzheimer's disease.

Animal models and research

Transgenic mouse models overexpressing human APP containing familial Alzheimer's disease mutations, such as the PDAPP mouse and the Tg2576 mouse, have been instrumental in studying disease mechanisms. These models recapitulate key features like amyloid plaque deposition, glial activation, and cognitive deficits. Research using Caenorhabditis elegans and Drosophila melanogaster has provided insights into conserved toxic gain-of-function effects. Furthermore, zebrafish models are used to study APP's role during development. These animal models are crucial for testing potential therapeutic interventions, including beta-secretase inhibitors, antibodies against amyloid-beta, and gamma-secretase modulators.

Regulation and expression

The expression of the APP gene is regulated at multiple levels, including transcriptional control, alternative splicing, and post-translational modification. The APP promoter contains binding sites for transcription factors such as SP1 and is influenced by inflammatory cytokines and oxidative stress. Alternative splicing in exon 7 and exon 8 generates isoforms like APP770 and APP751, which contain a Kunitz protease inhibitor domain and are more abundant in peripheral tissues. Post-translational modifications include N-glycosylation, phosphorylation, and tyrosine sulfation, which affect its trafficking and processing. Expression is high in the brain, particularly in neurons, but the protein is also found in platelets, leukocytes, and other cell types.

Category:Genes on human chromosome 21 Category:Alzheimer's disease-related proteins